GlassScriptPhysician profile
Sarah E Churton
NPI 1740509157
$4,145.12
in general payments reported to CMS, 2019-2025
29 companies · $620 in 2025
The $620 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $100 · 2021: $430 · 2022: $420 · 2023: $1,122 · 2024: $1,044 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.90 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $528.85 | 2021-2024 | Xeomin |
| Janssen Biotech, INC. | $436.93 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $411.42 | 2021-2025 | Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $398.99 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $301.17 | 2021-2025 | Blu-U |
| Genzyme Corporation | $300.14 | 2019-2025 | |
| Lilly USA, LLC | $209.29 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $195.79 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $168.36 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $151.24 | 2019-2023 | Valchlor |
| Novartis Pharmaceuticals Corporation | $110.29 | 2020-2024 | |
| Incyte Corporation | $107.30 | 2021-2024 | Opzelura |
| Almirall LLC | $90.38 | 2021-2024 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.05 | 2023-2025 | Spevigo |
| Revance Therapeutics, INC. | $77.19 | 2024-2025 | Daxxify |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.17 | 2020-2023 | Otezla |
| Allergan, INC. | $72.62 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $69.72 | 2023 | |
| Leo Pharma INC. | $53.56 | 2021-2022 | |
| Kyowa Kirin, INC. | $49.90 | 2025 | |
| Organogenesis INC. | $42.57 | 2021-2025 | Puraply Wound Matrix |
| Ucb, INC. | $36.91 | 2024 | Bimzelx |
| Biofrontera INC. | $36.29 | 2020-2021 | |
| Kerecis Limited | $35.53 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Strata Skin Sciences, INC. | $28.99 | 2025 | Xtrac |
| Genentech USA, INC. | $28.21 | 2019-2021 | |
| Convatec INC. | $16.91 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.27 | 2023 | Sotyktu |
| Vyne Pharmaceuticals INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Churton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.